- Home
- DNP vs SLNO Comparison
DNP vs SLNO Comparison
Compare DNP & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DNP | SLNO |
|---|---|---|
| Founded | 1986 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 2.5B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | DNP | SLNO |
|---|---|---|
| Price | $10.05 | $51.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $110.90 |
| AVG Volume (30 Days) | 479.6K | ★ 1.8M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $154,887,179.00 | $98,675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $155.86 |
| P/E Ratio | $4.26 | ★ N/A |
| Revenue Growth | ★ 3.30 | N/A |
| 52 Week Low | $8.69 | $41.50 |
| 52 Week High | $10.04 | $90.32 |
Technical Indicators
Market Signals| Indicator | DNP | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 46.06 | 48.33 |
| Support Level | $10.00 | $47.80 |
| Resistance Level | $10.35 | $53.10 |
| Average True Range (ATR) | 0.11 | 2.47 |
| MACD | -0.02 | 1.09 |
| Stochastic Oscillator | 14.29 | 79.48 |
Price Performance
Historical ComparisonAbout DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.